SCHEMBL3565874

SCHEMBL3565874

CC(C)Nc1nc(Cl)ncc1F

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.53
ALDH1A1 P00352 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
BCL6 P41182 1/20 0.42
TDP1 Q9NUW8 2/20 0.39
GAA P10253 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
ADORA3 P0DMS8 1/20 0.36
ADORA1 P30542 1/20 0.36
GLP1R P43220 1/20 0.34
SYK P43405 2/20 0.34
MAPK14 Q16539 1/20 0.33
MAPT P10636 1/20 0.33
RPS6KA3 P51812 1/20 0.33
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
NPC1 O15118 1/20 0.33
TP53 P04637 1/20 0.33
HPGD P15428 1/20 0.33
HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22866314 0.83 ALDH1A1 (0.49) KMT2AALDH1A1L3MBTL1BCL6TDP1
SCHEMBL31521348 0.82 ALDH1A1 (0.48) KMT2AALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL31521352 0.82 ALDH1A1 (0.48) KMT2AALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL1935093 0.81 TDP1 (0.42) KMT2AALDH1A1L3MBTL1BCL6TDP1
SCHEMBL22866264 0.81 ALDH1A1 (0.50) KMT2AALDH1A1L3MBTL1SMN1; SMN2ADORA3
SCHEMBL18634006 0.80 ALDH1A1 (0.43) KMT2AALDH1A1L3MBTL1BCL6SMN1; SMN2
SCHEMBL15357783 0.79 BCL6 (0.37) KMT2ABCL6SYKMAPK14RPS6KA3
SCHEMBL19675890 0.79 TDP1 (0.41) KMT2AALDH1A1L3MBTL1TDP1GAA
SCHEMBL16784842 0.79 ALDH1A1 (0.46) KMT2AALDH1A1L3MBTL1BCL6GAA
SCHEMBL653243 0.79 KMT2A (0.47) KMT2AALDH1A1L3MBTL1GAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025096957-A1 RAS-PI3K INHIBITORS AND USES THEREOF VIVIDION THERAPEUTICS, INC. (US) 2025-05-08 WO disclosed
CN-112055711-B Cyclohexylic acid triazolazine as LPA antagonist 百时美施贵宝公司 2024-07-23 CN disclosed
EP-3728223-B1 CYCLOHEXYL ACID TRIAZOLE AZINES AS LPA ANTAGONISTS BRISTOL MYERS SQUIBB CO (US) 2022-12-28 EP disclosed
US-11267800-B2 Cyclohexyl acid triazole azines as LPA antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 2022-03-08 US disclosed
US-20210230143-A1 CYCLOHEXYL ACID TRIAZOLE AZINES AS LPA ANTAGONISTS BRISTOL MYERS SQUIBB CO (US) 2021-07-29 US disclosed
EP-3191489-B1 PYRROLOPYRIMIDINES FOR USE IN INFLUENZA VIRUS INFECTION JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) 2021-01-06 EP disclosed
CN-112055711-A Cyclohexyl acid triazole azines as LPA antagonists 百时美施贵宝公司 2020-12-08 CN disclosed
EP-3728223-A1 CYCLOHEXYL ACID TRIAZOLE AZINES AS LPA ANTAGONISTS Bristol-Myers Squibb Company (US) 2020-10-28 EP disclosed
US-9932346-B2 Pyrrolopyrimidines for use in influenza virus infection JANSSEN SCIENCES IRELAND UC (IE) 2018-04-03 US disclosed
US-9932346-B2 Pyrrolopyrimidines for use in influenza virus infection JANSSEN SCIENCES IRELAND UC (IE) 2018-04-03 US disclosed
US-20170253600-A1 PYRROLOPYRIMIDINES FOR USE IN INFLUENZA VIRUS INFECTION JANSSEN INFECTIOUS DISEASES BVBA (BE) 2017-09-07 US disclosed
US-20170253600-A1 PYRROLOPYRIMIDINES FOR USE IN INFLUENZA VIRUS INFECTION JANSSEN INFECTIOUS DISEASES BVBA (BE) 2017-09-07 US disclosed
US-20110166146-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS SUNOVION PHARMACEUTICALS INC. (US) 2011-07-07 US disclosed
US-20110166146-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS SUNOVION PHARMACEUTICALS INC. (US) 2011-07-07 US disclosed
US-7820648-B2 Pyrimidine derivatives for the treatment of abnormal cell growth PFIZER INC (US) 2010-10-26 US disclosed
US-20080234303-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER INC 2008-09-25 US disclosed
EP-1966207-A2 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH Pfizer Products Inc. (US) 2008-09-10 EP disclosed
WO-2007072158-A2 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER PRODUCTS INC. (US) 2007-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166146-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS PAICS, ITPA, DPYD KMT2A 3191/4885ALDH1A1 269/4885L3MBTL1 4640/4885
US-11267800-B2 Cyclohexyl acid triazole azines as LPA antagonists LPAR3, LPAR1, LPAR2 KMT2A 1913/4885ALDH1A1 2244/4885L3MBTL1 4166/4885
US-20210230143-A1 CYCLOHEXYL ACID TRIAZOLE AZINES AS LPA ANTAGONISTS LPAR3, LPAR1, LPAR2 KMT2A 1913/4885ALDH1A1 2244/4885L3MBTL1 4166/4885
US-20080234303-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH CCNB1, TYMS, CCNA1 KMT2A 1056/4885ALDH1A1 714/4885L3MBTL1 704/4885
US-20170253600-A1 PYRROLOPYRIMIDINES FOR USE IN INFLUENZA VIRUS INFECTION IMPDH1, IMPDH2, TYMP KMT2A 2122/4885ALDH1A1 211/4885L3MBTL1 4003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.